Both individual investors who control a good portion of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) along with institutions must be dismayed after last week's 9.4% decrease
![AUPH - Aurinia Pharmaceuticals Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ) AUPH - Aurinia Pharmaceuticals Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)](https://images.fintel.io/us-auph-put-call-ratio.png)
AUPH - Aurinia Pharmaceuticals Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ)
![Saanich-based pharmaceutical company stocks double in value after successful lupus drug trial - Oak Bay News Saanich-based pharmaceutical company stocks double in value after successful lupus drug trial - Oak Bay News](https://www.bpmcdn.com/f/files/oakbay/import/2019-12/19682621_web1_191206-SNE-AurinaLupusDrugSuccess_1.jpg;w=1200;h=800;mode=crop)
Saanich-based pharmaceutical company stocks double in value after successful lupus drug trial - Oak Bay News
![Aurinia Pharmaceuticals Stock Forecast: down to 3.352 USD? - AUPH Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis Aurinia Pharmaceuticals Stock Forecast: down to 3.352 USD? - AUPH Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis](https://walletinvestorstorage.b-cdn.net/forecast-graphs/26/stock-auph-stock-forecast.png?v=1698694872)
Aurinia Pharmaceuticals Stock Forecast: down to 3.352 USD? - AUPH Stock Price Prediction, Long-Term & Short-Term Share Revenue Prognosis with Smart Technical Analysis
![Earnings call: Aurinia Pharmaceuticals reports robust Q3 2023 results, explores strategic options By Investing.com Earnings call: Aurinia Pharmaceuticals reports robust Q3 2023 results, explores strategic options By Investing.com](https://i-invdn-com.investing.com/news/LYNXNPEC3B0CQ_M.jpg)